• Increase
  • Decrease
  • Normal

Current Size: 100%

Media Library

Take Home Messages about WM

Morie Gertz, MD, Mayo Clinic, Rochester, 2019 Ed Forum
Teaches us about the incidence rates of WM, prevalence of IgM MGUS and smoldering WM, how MYD88 and CXCR4 impact outcomes in WM, MYD88 and transformation risk, hyperviscosity and when therapy is required, how WM affects the kidney (including amyloidosis), chemotherapy treatment of WM, how long responses last until new therapy is required, and strategies to monitor and manage adverse events associated with novel therapies for WM

Great Debates in WM

Moderated by Carl Harrington- IWMF President
Rituxan Maintenance vs. No Maintenance
Morton Coleman MD – Weill Cornell Medical College vs. Stephen Ansell MD, PhD – Mayo Clinic, 2019 Ed Forum
Limited Treatment Duration vs. Continuous Pill
Edward Stadtmauer, MD – University of Pennsylvania vs. Jorge Castillo, MD – Dana Farber Cancer Institute, 2019 Ed Forum
The experts debate hot topics in long term treatment decisions for WM

Peripheral Neuropathy

Tom Hoffmann, MD – IWMF Trustee, 2019 Ed Forum
Provides an in-depth review of the epidemiology, etiology, common cancers causing peripheral neuropathy, drugs related neuropathies, how neuropathy is evaluated, what tests are ordered, and facts about peripheral neuropathy relative to WM, including available treatments.

Cancer and Fatigue

Colleen Erb, MSN, CRNP, ACNP-BC, AOCNP– University of Pennsylvania, 2019 Ed Forum
Reviews cancer-related fatigue relative to quality of life issues, what causes fatigue to worsen, treatable contributing factors, other than disease or chemotherapy, other diseases that can add to fatigue, and what are the general strategies to manage fatigue

Pages

Subscribe to RSS - Media Library